Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9540539 | 0.78 | KEAP1 (0.54) | HDAC8HDAC6ALDH1A1MAPK1FFAR1 | |
| SCHEMBL6560456 | 0.77 | CES1 (0.44) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL3604456 | 0.77 | CES1 (0.50) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL6440598 | 0.75 | HDAC1 (0.57) | HDAC8HDAC6MAPK1L3MBTL1FFAR1 | |
| SCHEMBL5578204 | 0.74 | CES1 (0.58) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL6471170 | 0.74 | CYP2C19 (0.46) | ALDH1A1TSHRLMNAGAAHTT | |
| SCHEMBL10628617 | 0.73 | CES1 (0.56) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL23093940 | 0.72 | CES1 (0.45) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL12095508 | 0.72 | CES1 (0.55) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL2241627 | 0.72 | CES1 (0.55) | CES1CES2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683073-B2 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-03-23 | — | — | US | claimed |
| US-20060135557-A1 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2006-06-22 | — | — | US | claimed |
| JP-7215970-A | — | — | None | — | — | JP | disclosed |
| CN-103185907-B | Lenticule optical sheet and use its back light unit and liquid crystal display | SKC HAAS DISPLAY FILMS CO., LTD. (KR) | 2016-03-16 | — | — | CN | disclosed |
| EP-1784431-B1 | SUPPORTED METALLOCENE CATALYST, METHOD OF PREPARING THE CATALYST AND METHOD OF PREPARING POLYOLEFIN USING THE CATALYST | LG CHEMICAL LTD (KR) | 2015-01-07 | — | — | EP | disclosed |
| US-8926777-B2 | Method for manufacturing high brightness optical sheet | SKC HAAS DISPLAY FILMS CO., LTD. (KR) | 2015-01-06 | — | — | US | disclosed |
| CN-103185907-A | Micro optical lens and backlight unit and liquid display using micro optical lens | Skc haas display film co ltd | 2013-07-03 | — | — | CN | disclosed |
| CN-103105636-A | Method for manufacturing high brightness optical sheet | SKC HAAS DISPLAY FILMS CO LTD | 2013-05-15 | — | — | CN | disclosed |
| US-20130078425-A1 | METHOD FOR MANUFACTURING HIGH BRIGHTNESS OPTICAL SHEET | SKC HAAS DISPLAY FILMS CO., LTD. (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8124557-B2 | Supported metallocene catalyst, method of preparing the catalyst and method of preparing polyolefin using the catalyst | LG CHEM, LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| EP-1640367-B1 | ISOQUINOLINE -1,3,4-TRIONE, THE SYNTHETIC METHOD AND THE USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2011-02-09 | — | — | EP | disclosed |
| US-6110933-A | AN ENZYME INHIBITOR TREATING PANCREATITIS, HEPATITIS, CHRONIC RENAL FAILURE, ENDOTOXIN SHOCK, GRAM-NEGATIVE SEPTIC SHOCK, ARTHRITIS, RESPIRATORY DISEASE, HEART DISEASE, ALLERGIC DISEASE, THROMBOSIS, ARTERIOSCLEROSIS, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| WO-2000000220-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ESTER OR AMIDE PLA2 INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
| EP-0741697-B1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-09-15 | — | — | EP | disclosed |
| CN-1197450-A | Esters and amides as phospholipase A2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-28 | — | — | CN | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| EP-0741697-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-13 | — | — | EP | disclosed |
| JP-H07215970-A | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF AND INTERMEDIATE FOR PRODUCING THE SAME | KUMIAI CHEM IND CO LTD | 1995-08-15 | — | — | JP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135557-A1 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | APP, PSEN1, AIFM1 | CES1 2677/4885CES2 4424/4885AKR1B1 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.